VIATRIS INC. Debt Securities, Available-for-sale, Amortized Cost
VIATRIS INC. (VTRS) had Debt Securities, Available-for-sale, Amortized Cost of $40.40 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-02-26
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $40.40M.
- 2024-12-31: Debt Securities, Available-for-sale, Amortized Cost $38.90M.
- 2023-12-31: Debt Securities, Available-for-sale, Amortized Cost $37.80M.
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost $38.00M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2025-12-31 | $40.40M 10-K · filed 2026-02-26 |
| 2024-12-31 | $38.90M 10-K · filed 2026-02-26 |
| 2023-12-31 | $37.80M 10-K · filed 2025-02-27 |
| 2022-12-31 | $38.00M 10-K · filed 2024-02-28 |
| 2021-12-31 | $38.10M 10-K · filed 2023-02-27 |
| 2020-12-31 | $37.50M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |